Identification of Key Genes and Pathways in Oxaliplatin-Induced Neuropathic Pain Through Bioinformatic Analysis
Yaling Lou,Xuting Xu,Ronghua Wang,Danfeng Yao
DOI: https://doi.org/10.2147/jpr.s452594
IF: 2.8319
2024-05-04
Journal of Pain Research
Abstract:Yaling Lou, 1 Xuting Xu, 2 Ronghua Wang, 1 Danfeng Yao 3 1 Department of Clinical Pharmacy, Huzhou Central Hospital (The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University), Huzhou, People's Republic of China; 2 Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital (The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University), Huzhou, People's Republic of China; 3 Department of Pharmacy, Huzhou Maternity & Child Health Care Hospital, Huzhou, People's Republic of China Correspondence: Danfeng Yao, Department of Pharmacy, Huzhou Maternity & Child Health Care Hospital, No. 2, East Street, Wuxing District, Huzhou, 313000, People's Republic of China, Email Background: The mechanism of Chemotherapy-induced neuropathic pain (NP) remains obscure. This study was aimed to uncover the key genes as well as protein networks that contribute to Oxaliplatin-induced NP. Material/Methods: Oxaliplatin frequently results in a type of Chemotherapy-induced NP that is marked by heightened sensitivity to mechanical and cold stimuli, which can lead to intolerance and discontinuation of medication. We investigated whether these different etiologies lead to similar pathological outcomes by targeting shared genetic targets or signaling pathways. Gene expression data were obtained from the Gene Expression Comprehensive Database (GEO) for GSE38038 (representing differential expression in the spinal nerve ligation model rats) and GSE126773 (representing differential expression among the Oxaliplatin-induced NP model rats). Differential gene expression analysis was performed using GEO2R. Results: Protein-protein interaction (PPI) analysis identified 260 co-differentially expressed genes (co-DEGs). Subsequently, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed three shared pathways involved in both models: Kaposi sarcoma-associated herpesvirus (KSHV) infection, Epstein-Barr virus (EBV) infection, and AGE-RAGE signaling pathway in diabetic complications. Further bioinformatics analysis highlighted eight significantly up-regulated genes in the NP group: Mapk14, Icam1, Cd44, IL6, Cxcr4, Stat1, Casp3 and Fgf2. Our results suggest that immune dysfunction, inflammation-related factors or regulating inflammation factors may also be related to Oxaliplatin-induced NP. Additionally, we analyzed a dataset (GSE145222) involving chronic compression of DRGs (CCD) and control groups. CCD model is a classic model for studying NP. We assessed these hub genes' expression levels. In contrast with the control groups, the hub genes were up-regulated in CCD groups, the difference was statistically significant, except Stat1. Conclusion: Our research significantly contributes to elucidating the mechanisms underlying the occurrence as well as the progression of Oxaliplatin-induced NP. We have identified crucial genes and signaling pathways associated with this condition. Keywords: neuropathic pain, oxaliplatin, spinal dorsal horn, bioinformatics, differentially expressed genes, hub genes Chemotherapy-induced neuropathic pain (CINP) is a progressive, persistent, and challenging disease characterized by pain, numbness, tingling sensation, and sensitivity to cold. It affects about 50–90% of individuals undergoing chemotherapy treatment. 1 CIPN is mainly induced by first-line chemotherapy drugs such as oxaliplatin, paclitaxel, and vinblastine. With the accumulation of chemotherapy drug toxicity, peripheral neuropathological symptoms become increasingly severe, compelling patients to reduce the chemotherapy drug dosages, shorten the chemotherapy cycle, or even discontinue medication, ultimately impacting patient survival rates. Chemotherapy-induced neuropathic pain (CINP) remains a therapeutic challenge with no effective drugs and treatments currently available. Oxaliplatin is a widely used chemotherapy-drug for the treatment of colorectal and advanced ovarian cancer. 2 However, one of the major side effects associated with oxaliplatin treatment is the development of neuropathic pain (NP). This condition is characterized by severe and painful peripheral neuropathy, which can often lead to dose reduction or early discontinuation of chemotherapy. 3,4 Despite its clinical significance, the exact mechanism underlying Oxaliplatin-induced neurotoxicity and the subsequent development of NP remains unclear. Inflammation of the dorsal root ganglions (DRGs) is the pivotal physiological basis for the occurrence of NP. During the process of pain generation, the DGRs serve as the primary neuron of pain input in the pain mechanism. So the DGRs are considered to be key participants within the pathogenesis that lead to NP.<s -Abstract Truncated-
clinical neurology